PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has emerged as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interest (POI) and another to an E3 ubiqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sajid, He, Yonghan, Zhang, Xuan, Yuan, Yaxia, Pu, Shaoyan, Kong, Qingpeng, Zheng, Guangrong, Zhou, Daohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319888/
https://www.ncbi.nlm.nih.gov/pubmed/32475992
http://dx.doi.org/10.1038/s41388-020-1336-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319888/
https://www.ncbi.nlm.nih.gov/pubmed/32475992
http://dx.doi.org/10.1038/s41388-020-1336-y

Ejemplares similares